Summary of outcome trials of drugs with cardiorenal benefits

Agent (outcome trial)	Population	Clinical outcomes (HR [95% CI] vs placebo)						
		MACE	CV mortality	All-cause mortality	Fatal/ nonfatal MI	Fatal/ nonfatal stroke	Hosp HF	Progression of CKD
GLP1-RA								
Exenatide (EXSCEL)	**CVD (73%) or CV risk factors**	0.91* (0.83-1.00)	0.88 (0.76–1.02)	**0.86 (0.77-0.97)**	0.97 (0.85–1.10)	0.85 (0.70–1.03)	–	–
Liraglutide (LEADER)	**CVD (72%) or CV risk factors**	**0.87* (0.78-0.97)**	**0.78 (0.66–0.93)**	**0.85 (0.74-0.97)**	0.86 (0.73–1.00)	0.86 (0.71–1.06)	–	–
Semaglutide SC (SUSTAIN 6)	**CVD (59%) or CV risk factors**	**0.74* (0.58-0.95)**	0.98 (0.65–1.48)	1.05 (0.74-1.50)	0.74 (0.51-1.08)†	**0.61 (0.38-0.99)†**	–	–
Semaglutide Oral (PIONEER 6)	**CVD (85%) or CV risk factors**	0.79* (0.57-1.11)	**0.49 (0.27–0.92)**	**0.50 (0.31-0.84)**	1.18 (0.73-1.90)†	0.74 (0.35-1.57)†	–	–
Dulaglutide (REWIND)	**CVD (31.5%) or CV risk factors**	**0.88* (0.79-0.99)**	0.91 (0.78–1.06)	0.90 (0.80-1.01)	0.96 (0.79-1.16)†	**0.76 (0.61-0.95)†**	–	–
Albiglutide (HARMONY) (withdrawn from market)	**CVD or PVD**	**0.78* (0.68-0.90)**	0·93 (0·73–1·19)	0.95 (0.79-1.16)	0.96 (0.79–1.15)	**0.76 (0.62–0.94)**	–	–
SGLT2i								
Empagliflozin (EMPA-REG)	**CVD**	**0.86* (0.74-0.99)**	**0.62 (0.49-0.77)**	**0.68 (0.57-0.82)**	0.87 (0.70–1.09)	1.18 (0.89–1.56)	**0.65 (0.50-0.85)**	**0.61 (0.53-0.70)**
Canagliflozin (CANVAS PROGRAM)	**CVD (66%) or CV risk factors**	**0.86* (0.75-0.97)**	0.87 (0.72-1.06)	0.87 (0.74-1.01)	0.89 (0.73–1.09)	0.87 (0.69–1.09)	**0.67 (0.52-0.87)**	**0.73 (0.67-0.79)**
Canagliflozin (CREDENCE)	**CKD (eGFR 30-90 + proteinuria)**	**0.80 (0.67-0.95)**	0.78 (0.61-1.00)	0.83 (0.68-1.02)	–	–	**0.61 (0.47-0.80)**	**0.70*[2] (0.59-0.82)**
Dapagliflozin (DECLARE-TIMI)	**CVD (41%) or CV risk factors**	0.93* (0.84-1.03)	0.98 (0.82-1.17)	0.93 (0.82-1.04)	0.89 (0.77–1.01)	1.01 (0.84–1.21)	**0.73 (0.61-0.88)**	**0.76 (0.67-0.87)**
Dapagliflozin (DAPA-HF)	**CHF (reduced EF) ± DM (42%)**	–[1]	**0.82 (0.69-0.98)**	**0.83 (0.71-0.97)**	–	–	**0.70 (0.59-0.83)**	0.71 (0.44-1.16)

* Primary outcome.
† Nonfatal events only.

Note: This table presents relative risk reduction versus placebo and NOT absolute risk reduction. Statistically significant results are shown in bold type, with cells outlined when this was the primary outcome. [1]DAPA-HF Primary Outcome = hospitalization for heart failure (Hosp HF) or cardiovascular (CV) death. Hazard ratio (HR) 0.74* (0.64-0.99), p<0.05. [2]Primary outcome = chronic kidney disease (CKD) progression or CV death. *ACS*, acute coronary syndrome; *CHF*, congestive heart failure; *CI*, confidence interval; *CVD*, CV disease; *DM*, diabetes mellitus; *EF*, ejection fraction; *eGFR*, estimated glomerular filtration rate in mL/minute/1.73m^2; *GLP1-RA*, glucagon-like peptide-1 receptor agonists; *HR*, hazard ratio; *MACE*, major cardiovascular events (CV death, nonfatal myocardial infarction [MI], nonfatal stroke); *MI*, myocardial infarction; *PVD*, peripheral vascular disease; *SGLT2i*, sodium-glucose cotransporter 2 inhibitors.